Posted by barbarahales
Mike Honda, the Democratic representative from California, plans to propose a bill establishing a new FDA Office of Mobile Health, according to Kaiser Health News. Honda feels that this is needed to support the mobile health industry. The role of the office would be to: Make recommendations on mobile health application issues Create a developer [...]
Posted by barbarahales
The FDA (Food and Drug Administration) has released a guide for social media involvement with everyone from patients to pharmaceutical companies and healthcare providers. With deliberation for the past 2 years, the FDA provides guidance in how information can be given or obtained through social media. The public has been given 90 days to respond. [...]
Posted by barbarahales
We have often seen that for many businesses, when following a code of ethics translates to losing money, their mantra is “there is no ethics in business”. Apparently this is what Glaxo- Smith-Klein subscribes to. In doing their comparison study between Avandia and Actos for diabetes, the cardiovascular risk and death came to light. Instead [...]
- July 13th
- Filed under: Uncategorized
- Tags: actos, avandia, business ethic, drug safety, drug warning, ethics, FDA, glaxo smith klein, GSK, patient safety, public warning